Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > SABC 2024 - Irene Study Results - Pelareorep in TNBC

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 02, 2024 11:34pm

79 Views

Post# 36294054

RE:RE:SABC 2024 - Irene Study Results - Pelareorep in TNBC

During hypoxic conditions, cells undergo critical adaptive responses that include the up-regulation of hypoxia-inducible proteins (HIFs) and the induction of the unfolded protein response (UPR). ONCY's pelareorep down-regulates HIF-1α levels and in so doing remodels the tumor microenvironment (TME) for sequential immune checkpoint inhibition.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec